China on Life Sciences, Biotechnology & Nanotechnology

在全球化背景之下，中国医药企业正站在创新与合作的新风口，迎接前所未有的发展契机。与此同时，海外投资者与医药企业亦在敏锐捕捉投$

In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.

Thanks to the heads up from Aaron Wininger , on 19 March 2025, the China National Medical Products Administration (NMPA) announced the draft Implementation Measures for Drug Trial Data Protection (IM), and their procedures.